Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Lung microbiome and coronavirus disease 2019 (COVID-19): Possible link and implications

Saroj Khatiwada a, b, *, Astha Subedi c

a School of Medical Sciences, UNSW Sydney, Australia
b Department of Biochemistry, Modern Technical College, Nepal
c Medicine ICU, Tribhuvan University Teaching Hospital, Nepal

A R T I C L E   I N F O

Keywords: Coronavirus disease (COVID-19) Immunity Infection Lung microbiome Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

A B S T R A C T

Coronavirus disease 2019 (COVID-19) is a rapidly emerging disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease begins as an infection of lungs, which is self-limiting in the majority of infections; however, some develop severe respiratory distress and organ failures. Lung microbiome, though neglected previously have received interest recently because of its association with several respiratory diseases and immunity. Lung microbiome can modify the risk and consequences of COVID-19 disease by activating an innate and adaptive immune response. In this review, we examine the current evidence on COVID-19 disease and lung microbiome, and how lung microbiome can affect SARS-CoV-2 infection and the outcomes of this disease.

To date there is no direct evidence from human or animal studies on the role of lung microbiome in modifying infection and immunity against viral infections. Future studies need to be undertaken to find the relationship between lung microbiome and COVID-19 disease.

1. Introduction

The rapid outbreak of the coronavirus disease (COVID-19) has crippled global health and economy [1]. As of 21st July 2020, it has affected 188 countries and infected 14,727,753 people causing death of 610,560 patients [2]. The rapid increase in the number of severely ill patients after COVID-19 infection across the globe has resulted in heavy investment in health care infrastructures and medical supplies. To stop the spread of the virus, many countries have imposed a strict international travel ban and put the population into home restriction [3]. The COVID-19 disease is caused by a virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged in Wuhan, China at the end of 2019 [4]. The disease is highly transmissible among persons through aerosols, and evidence shows the virus can remain viable for up to 3 days on plastic and stainless steel, all of which facilitates the easy propagation of this virus [5].

The usual symptoms of COVID-19 include fever, dry cough, and tiredness. Some patients may have aches and pains, nasal congestion, anosmia, sore throat or diarrhea [6]. A large majority of patients may not develop any symptoms after the viral infection, thereby acting as a hidden carrier for this devastating disease [7]. The common complications of COVID-19 that lead to death include acute respiratory failure (ARF), pneumonia, acute respiratory distress syndrome (ARDS), acute liver injury, acute cardiac injury, acute kidney injury, septic shock, disseminated intravascular coagulation, blood clots and rhabdomyolysis [8–11]. The development of pneumonia or acute respiratory illness is consistently observed after COVID-19 infection with the majority of the patient showing lesions involving bilateral lungs, which is often the common cause of COVID-19 death [10,12,13].

Microbiome refers to the collective genomes of all the microorganisms. It includes every organism (not only bacteria, but also archaea, fungi and viruses), DNA and RNA species, and proteins that can affect health and development of diseases [14]. Microbiota refers to the community of microorganisms, including bacteria, viruses, fungi, and

Abbreviations: ACE2, Angiotensin converting enzyme; ARDS, Acute respiratory distress syndrome; ARF, Acute respiratory failure; COPD, Chronic obstructive pulmonary disease; COVID-19, Coronavirus disease 2019; CRP, C reactive protein; IFN, Interferon; PAMP, Pathogen associated molecular patterns; PRR, Pattern recognition receptor; rRNA, Ribosomal RNA; RSV, Respiratory syncytial virus; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; TNF, Tumour necrosis factor.

* Corresponding author at: School of Medical Sciences, UNSW Sydney, Australia.
E-mail address: khatiwadasaroj22@gmail.com (S. Khatiwada).

https://doi.org/10.1016/j.humic.2020.100073

Available online 5 August 2020
2452-2317/© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
protozoans, that live in a host body [15]. The COVID-19 disease begins with the invasion of lungs by SARS-CoV-2 virus, and the major complications that develop subsequently are related to lung infection and immune response generation, therefore, lung microbiome might play an important role from initiation to the progression of this disease [16].

This review focuses on the potential relationship between COVID-19 disease and lung microbiome. We summarized the most important findings on lung microbiome and its role in immunity and lung disease including COVID-19. We searched for the keywords (SARS-CoV-2) OR (coronavirus disease 2019) OR (COVID-19) AND (microbiome) in PubMed and Scopus for the articles until 20 July 2020. All the original research articles reporting microbiome in COVID-19 were included. We highlight the role of the lung microbiome, and how the microbiome can modulate SARS-CoV-2 attack along with the consequences of viral attack. Finally, we seek the potential role of lung microbiome and immunity in severity of COVID-19 disease. We also discuss the relevant studies supporting the role of microbiome against viral infection and disease complications.

2. Lung microbiome in health and disease

2.1. Microbiome in healthy lung

Until very recently, the lung was considered to be a sterile site free from bacteria [17]. Being an environment with favourable temperature, moisture and mucus, and a large surface area that is in regular contact with the external environment, the lung is indeed a microbiome rich site [18]. Lung microbiome is more dynamic and transient than that of the gastrointestinal tract because of bidirectional movement of air and mucus [19,20]. In a healthy human, the lung microbiota has a low density but harbours a prominent diversity of interacting microbiota. At the phylum level, Firmicutes, Bacteroidetes and Proteobacteria are the most common phyla. At the genus level, Prevotella, Veillonella and Streptococcus are the predominant microorganisms [17,21]. The composition of lung microbiome is mainly determined by microbial immigration, elimination, and relative growth rates of its members. In lung diseases, these factors can change, and therefore overgrowth of one species with reduction of microbial diversity occurs (shown in Fig. 1) [22].

2.2. Microbiome in lung diseases

During lung pathology, drastic changes in the local environment occur, creating a favourable environment for a specific microbial growth. In one of the common lung disease, asthma, bronchoscopy samples have shown an increased abundance of Haemophilus, Neisseria, Fusobacterium, and Porphyromonas [23,24]. Recent evidence shows microbiota administration through the oral or intranasal route as probiotics can lower allergic inflammation seen in asthma, highlighting the intricate relationship between microbiota and asthma [25]. In another common lung disease, chronic obstructive pulmonary disease (COPD), Lactobacillus, Fusobacteria, Leptotrichia and Fusobacterium were observed in abundant numbers [26,27]. The most abundant bacteria seen in cystic fibrosis were Pseudomonas, Staphylococcus, Stenotrophomonas, Achromobacter, and Streptococcus [28,29]. Recent evidence shows that lung microbiome is altered in lung cancer, and the microbiome can influence cancer development and progression [30,31].

Emerging evidence shows the relationship between lung microbiota and susceptibility to pneumonia [32]. Pneumonia is a widespread lung disease characterised by infection of lung alveoli leading to an infiltration of inflammatory cells and fluids into the alveoli. This disease can be caused by bacteria, virus, fungi or protozoans [33]. Streptococcus pneumoniae and Haemophilus influenzae type b are the most common bacterial causative agents, whereas, respiratory syncytial virus (RSV) is the most common viral agent for pneumonia [34,35]. The endotracheal aspirates of patients with ventilator associated pneumonia had a higher bacterial load but a lower abundance of bacterial class, Bacilli, than matched controls [36]. Similarly, the microbiota profile of endotracheal aspirates was different between the mechanically ventilated pneumonia group and the non-pneumonia group. In the intubated patients with pneumonia, Pseudomonas, Corynebacterium, and Rothia were more abundant, while Streptococcus and Prevotella were less abundant as compared to those without pneumonia [37]. The abundance of Firmicutes phyla was reduced in the patients with interstitial pneumonia including the overall phyla richness as compared to healthy group. The abundance of Streptococcus phyla was significantly reduced in interstitial pneumonia patients, while Prevotella and Veillonella were enriched in comparison to healthy volunteers [38]. In addition, the microbial diversity and composition tended to differ according to the causative agent of pneumonia, which
suggests that lung microbiome can vary according to the type of pneumonia [39]. Overall, pneumonia is characterized by a shift in lung microbiome, with domination by pneumonia etiologic agent, high microbial biomass, and lowering of microbial diversity [33].

The composition and diversity of upper respiratory tract and lung microbiome have been found to shift in response to respiratory viral infections in humans and animals [40–42]. Some of the common viruses invading respiratory tract and lungs include rhinovirus, influenza virus, adenovirus, parainfluenza virus and RSV. These respiratory viral infections are quite common during childhood, and they often increase susceptibility to secondary bacterial infection of lungs [41]. The upper respiratory tract microbiome of rhinovirus and RSV infected infants was found to be largely dominated by Moraxella, Streptococcus, Corynebacterium, Haemophilus, and Dolocegranum [40]. In another study, rhinovirus infection was found to increase the relative abundance of Haemophilus and Neisseria, both of which are associated with secondary lung infections [43]. In mice, influenza virus infection of lungs caused a shift in the composition and diversity of microbial community. The viral infection changed the dominant bacterial class from Alphaproteobacteria to Gammaproteobacteria and Actinobacteria, and this was followed by an increase in the relative abundance of Streptococcus and Staphylococcus [44]. In summary, the lung microbiome is highly dynamic, and infections (bacterial, viral) can lead to rapid alterations in the lung microbiome, and the microbial communities can play a critical role in those infections (shown in Fig. 1).

3. Lung immunity

The alveolar surface is the largest surface area in direct contact to the external environment, so it is constantly exposed to invading microorganisms. Therefore, it harbours several lines of defence against potential infections. A continuous layer of pulmonary epithelial cells constitutes a physical and biological barrier for inhaled substances and pathogens. The mucus coating of the pulmonary epithelium, proteolytic enzymes, defence proteins (immunoglobulins, lactoferrin, defensins) and lysosomes present on the surface and in the fluids around alveoli protect against infection [18]. Pulmonary epithelial cells are in close contact with cells of the immune system, and they also secrete a wide range of cytokines and chemokines. They express cell surface receptors called pattern-recognition receptors (PRRs), such as the toll-like receptors (TLRs), which enable them to recognize pathogen-associated molecular patterns (PAMPs) from viruses, bacteria, fungi, protozoa, and multicellular parasites [45].

Apart from the above mentioned immune mechanisms, lung contains immune cells such as dendritic cells, macrophages (alveolar and interstitial), lymphocytes (T-cells, γδ T cells, NK cells, B-cells), innate lymphoid cells and neutrophils that support innate and adaptive immune mechanism [46]. All these immune cells are involved in eliminating antigens and pathogens from the respiratory tract through phagocytosis or activation of effector molecules that remove antigens. Regulatory T cells resident within the lungs are vital for the maintenance of immune tolerance to airborne particles, and they are directly influenced by local microbiota [45]. Another type of T cells, called lung resident memory γδ T cells provide a rapid immune response at barrier surfaces to recall antigens previously encountered through lung mucosa, which is apart from its role in cytokine and interferon production to stop viral and bacterial infection [47]. Despite the existing immunity mechanisms, lung infection is unavoidable. In the next section, we will discuss how SARS-CoV-2 initiates lung infection and escape the immune response.

4. SARS-CoV-2 infection and virus immuno-evasion mechanism

In the respiratory tract, SARS-CoV-2 bind to the specific host receptors called angiotensin-converting enzyme 2 (ACE2). This virus has an envelope-anchored spike protein that facilitates virus entry into host cells by first binding to ACE2. The virus then enters the host cell through endocytosis [48]. Inside the cells, the viral genome replicates and makes necessary proteins, which assemble to form new virions. The newly released virions can invade other lung cells [4,49]. The stress of viral production will lead to cell death, which in turn will trigger a series of immune responses and initiate inflammation reflected as lymphopenia, elevated C reactive protein (CRP) and erythrocyte sedimentation rate [13].

The viral RNAs and PAMPs are detected by the PRRs, such as TLRs inside the cells [50]. The recognition will lead to the activation of the transcription factor nuclear factor-kB (NF-κB) and interferon regulatory factor 3 (IRF3) to induce proinflammatory cytokines such as interferon-α and tumour necrosis factor-beta (TNF-β). The production of type I interferons (IFN) will cause suppression of viral multiplication and prevent the severity of disease [51]. Increase in interleukin-6 (IL-6), CRP, and chemokines such as interferon-γ-inducible protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1-alpha (MIP-1A), and tumour necrosis factor-alpha (TNF-α) were observed in COVID-19 patients [10,52].

If the body immune response cannot stop the SARS-CoV-2 multipliation, then a massive degree of lung injury occurs. This degree of damage can generate a substantial immune response from immune effector cells which is characterized by a large amount of cytokines (IFN-α, IFN-γ, IL-1β, IL-6, IL-12, IL-18, IL-33, and TNF-α) and chemokines (CCL2, CCL3, CCL5, CXCL8, CXCL9, and CXCL10) in the body [53]. This condition of hyperinflammation manifested as ‘cytokine storm’ is called as COVID-19 ARDS. This is one of the most dangerous and potentially life-threatening events related to COVID-19 disease [54]. Besides, SARS-CoV-2 infection damages the pulmonary lining altering the composition of normal microbiota, and can promote the growth of specific bacteria to initiate secondary pneumonia [41].

SARS-CoV-2 deploys several evasion mechanisms for defeating host cells. One of the ways is the formation of double-membrane vesicles that lack PRRs, where the virus replicates, leading to failure of recognition by immune cells and therefore avoid host detection [53]. Another feature of this virus, eight surface proteins, can block the action of interferon I, causing the cells to fail to stop viral multiplication [55]. The virus has also developed a strategy to stop host cell recognition by mimicking host cell capping machinery [51]. The SARS-CoV-2 viral infection occurs amid the local environment of diverse microbiota; therefore, it is apparent that lung microbiota can have an impact on the initiation, development, and progression of the COVID-19 disease.

5. Lung microbiome and COVID-19 disease

5.1. Roles of the lung microbiome

Lungs are at the frontline of immunity as they are constantly exposed to a wide variety of external environment. The microbiome has a principal role in shaping pulmonary immunity, and healthy lung has a vast array of microbiota. Microbes boost innate and adaptive immunity (site-specific in lungs and systemic), release factors which assist respiratory functions, and prevent an invasion of lungs from pathogens [56]. The normal microbiota restricts the growth of harmful pathogens that may make their way into the lungs. This growth restriction may occur by several mechanisms, such as, limiting nutrients access and secreting growth inhibitors [57].

Activation of lung immune cells that initiates innate and adaptive immunity requires microbe exposure [58]. The function of one of the vital effector and regulator cells of the lung, γδ T cells, depends on pathogen invasion [47,59]. Evidence shows that exposure to certain bacterial strains in neonate protects against excessive airway inflammation through the alteration of immune cells [60]. Furthermore, microbial exposure is required for developing innate immunity, as children exposed to the microbial rich environment had a lower rate of asthma and allergic sensitization, and stronger immunity [61]. One of the
products of lung’s normal flora showed an allergo-protective effect in the animal model of airway inflammation [62]. In summary, previous studies highlight that lung immunity development requires exposure to diverse microbes (shown in Fig. 1).

5.2. Lung microbiome in COVID-19 disease

To date, only few studies have explored the microbiome of COVID-19 patients. Emerging evidence from these studies shows that microbial communities in the gut and lung are altered in COVID-19 patients, and the alterations may have a critical impact on the immunity and severity of COVID-19 disease [42,63–66]. Though primarily a respiratory virus, the SARS-CoV-2 virus has also been found in the faecal samples from COVID-19 patients. The gut microbiome of COVID-19 patients had a significant reduction of bacterial diversity, and a significantly higher relative abundance of opportunistic pathogens such as Streptococcus, Rothia, Veillonella, and Actinomyces, and a lower abundance of beneficial symbionts as compared to control group. Thus, it appears that gut microbial communities interact with SARS-CoV-2 virus [42].

Aspergillus flavus

In another pilot study of 15 COVID-19 patients, the gut microbiome was characterized by enrichment of opportunistic pathogens (Clostridium hathewayi, Actinomyces viscosus and Bacteroides nordii) and depletion of beneficial commensals (Eubacterium ventriosum, Faecalibacterium prausnitzii, Roseoburia, Lachnospiraceae taxa) [66]. Moreover, this study showed the severity of COVID-19 disease is directly correlated with the predominance of opportunistic pathogens (Clostridium ramosum and Clostridium hathewayi) and inversely with the predominance of beneficial commensals (Alistipes onderdonkii and Bacteroides ovatus) [66]. Similarly, COVID-19 patients had increased proportions of opportunistic fungal pathogens, Candida albicans, Candida auris, and Aspergillus flavus as compared to controls [65]. In summary, the role of gut microbiome against SARS-CoV-2 infection and disease severity is rapidly emerging, and therefore gut microbiota may be developed as therapeutics for the management of COVID-19 disease in future.

Till date, only two studies have analysed the lung microbiome of COVID-19 patients [63,64]. In one of the study, bronchoalveolar lavage fluid from COVID-19 patients (n = 8), community-acquired pneumonia patients (n = 25) and healthy controls (n = 20) was investigated, and a significant difference in microbiota composition was observed [64]. Both COVID-19 and community-acquired pneumonia patients had enrichment of pathogenic and commensal bacteria, indicating a degree of microbial dysbiosis in both diseased states [64]. In the other study, the lung post-mortem biopsies from 20 deceased COVID-19 patients were used to study lung microbiome. The most common bacterial genera were Acinetobacter, Chryseobacterium, Burkholderia, Brevundomonas, Sphingobium, and Enterobacteriaceae. The most common fungal genera were Cutaenoichrosporon, followed by Issatchenka, Wallemia, Cladosporium, Alternaria, Dipodascus, Mortierella, Aspergillus, Naganishia, Diutina, and Candida [63]. Therefore, a mix of bacterial and fungal infection was seen in the COVID-19 patients of this study. Overall, there is very little information about the composition of lung microbiome in COVID-19 patient. Further studies with bigger sample size are required to know more precisely the composition and the role of lung microbiome in the severity of SARS-CoV-2 infections.

5.3. Role of the lung microbiome in COVID-19 disease and COVID-19 ARDS

Although there is no direct evidence if lung microbiome can affect potential SARS-CoV-2 infections and the outcomes of this disease, yet several lines of evidence support that bacteria in lungs have important roles in this disease. Firstly, microbiota dwelling on the respiratory surface can acts as a barrier, thereby preventing viral attachment to host cells. Secondly, microbiota prime the lung immunity, which will fight against viral infection, and exposure to a diverse range of microbiota may build a wider immunity. Such phenomenon is particularly common in the gut, where gut microbiota can protect against potential flu viral infections [67]. In mice, the nasal application of a respiratory normal flora, Corynebacterium pseudodiptheriticum, increased the TLR3 antiviral response against RSV and enhanced the production of TNFa, IL-6, IFNγ, and IFNβ [68]. Another respiratory tract flora, Staphylococcus aureus, protected against influenza induced lung injury [69]. Recent evidence of the association between COVID-19 disease severity with the gut microbiota seems highly promising [66]. Thus, it appears that lung microbiome may modify propensity to SARS-CoV viral infection.

Till date, it is unknown if lung microbiota can modify the risk of developing severe respiratory complications such as ARDS after SARS-CoV-2 infection. The dysbiosis of lung microbiome may contribute to COVID-19 ARDS because microbial dysbiosis is found to provoke a dysregulated immune response leading to inflammation [22,54,70]. In the ARDS unrelated to COVID-19 disease, lung microbiome is found to be enriched with gut-associated bacteria, which demonstrates the relationship between lung microbiome and ARDS [71]. Recently, the altered microbiome (increase in bacterial burden and a decrease in alpha diversity) was shown to be associated with inflammation and mortality in ARDS patients. The change in microbiota population (a reduction in Betaproteobacteria and an increase in Staphylococcus, Streptococcus and Enterobacteriaceae) was significantly associated with serum cytokine β6 [72]. Lung microbiome seems to have a critical role in severely ill patients because a recent study found that lung microbiota predicts the clinical outcome and death in those patients [73]. This study showed that increased lung bacterial burden and lung enrichment with gut-associated bacteria were predictive of adverse consequences of ARDS. Thus, in COVID-19 ARDS, the microbiome may have a significant role in determining the severity of the disease, and the outcomes of ARDS. In the future, studies will find if the presence of a specific bacterial population is associated with low risk for SARS-CoV-2 infection and ARDS development.

6. Immunity, COVID-19, and future implications

Based on the current evidence, it appears that immunity is at the forefront for protection against COVID-19 disease. Immunity development is a continuous process and requires exposure to a range of microbiota and environments [74]. Exposure of human population to diverse air microbes that may occur in unhygienic environment is believed to develop more robust immunity, and this may partly account for the variation in the COVID-19 death rate among countries [75]. Several other factors such as the method of delivery at birth, air microbiota of the immediate environment, prenatal and childhood exposures to microbes, respiratory viral illness, indoor and outdoor pollution can have a critical influence in the microbiome composition and immunity development in children [45]. Exposure to air with high air microbial load is found to reduce asthma risk in children [76]. In many developed countries, over the years, there has been a change in diet, sanitary conditions, antibiotics use, exposure to environmental chemicals and the change in the living environment, all of which may have ultimately reduced the exposure to diverse microbes. This factor is believed to be one of the principal factors for the current rise in the number of autoimmune lung diseases, and weak immunity [32,74].

Till date little is known about the role of lung microbiome in COVID-19 disease. Future studies are highly warranted to solve the complex relationship between lung immunity, lung microbiome and SARS-CoV-2 infection along with this disease complications. Because of the therapeutic benefits of microbiota as probiotics, future studies should also focus on the potential benefits and applicability of microbiota transplantation for the COVID-19 disease. We also emphasize collecting bronchoalveolar samples from the COVID-19 infected patients and perform 16S rRNA gene sequencing in a large sample size.
7. Conclusions
We conclude that lung microbiome can have a profound impact on the susceptibility to SARS-CoV-2 infection and severity of the disease. Moreover, lung microbiome has important contribution for the generation of immune responses against viral attack, and microbiome may affect the outcome of COVID-19 ARDS. Future studies should investigate lung microbiome and immune response in a large cohort of COVID-19 patients, and correlate with the severity of this disease. Future studies should also assess if probiotics treatment can improve COVID-19 disease.

8. Ethics approval and consent to participate
Not required

9. Consent for publication
Not applicable

10. Availability of data and material
Not applicable

Funding
None

Author contributions
Both SK and AS involved in conceptualization, literature review, writing the original draft and review of the draft.

Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgement
The figure was created using BioRender.com.

References
[1] WHO. Coronavirus disease (COVID-2019) situation reports; 2020 [Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/].
[2] CSSE JHU. Wuhan coronavirus (2019-nCoV) global cases; 2020.
[3] Nicola M, Afzal Z, Solzbach C, Korwan A, Al-Jabir A, Josifidis C, et al. The socioeconomic implications of the coronavirus and COVID-19 Pandemic: a review. Int J Surg 2020.
[4] Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020;24:491–8.
[5] van Dooremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020;382(16):1564–7.
[6] WHO. Q&A on coronaviruses (COVID-19); 2020 [Available from: https://www.who.int/news-room/q-a-detail/q-a-coronaviruses#:~:text=symptoms.
[7] Day M. Covid-19: four fifths of cases are asymptomatic, China figures indicate. BMJ 2020;369:m1375.
[8] Practice BB. Coronavirus disease 2019 (COVID-19) Complications 2020.
[9] Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020; 368:m1091.
[10] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506.
[11] Siordia JA. Epidemiology and clinical features of COVID-19: A review of current literature. J Clin Virol 2020;127:104357.
[12] Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis. 2019.
[13] Zhu J, Ji P, Fang J, Zhong Z, Li H, He C, et al. Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis. J Med Virol. n/a(n/a).
[14] Moffat MF, Cookson WO. The lung microbiome in health and disease. Clin Microbiol Rev 2017;30(1):255–9.
[15] Duman A, Bernard L, Poquet Y, Lugo-Villarino G, Neyrolles O. The role of the lung microbiota and the gut–lung axis in respiratory infectious diseases. Cell Microbiol 2018;20(12):e12966.
[16] Yuki K, Fujisugi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. Clin Microbiol Rev 2020;215:108427-
[17] Dickson RP, Erb-Downward JR, Martinez FJ, Huffnagle GB. The microbiome and the respiratory tract. Annu Rev Physiol 2016;78:481–504.
[18] Invernizzi R, Lloyd CM, Molyneux PL. Respiratory microbiome and epithelial interactions shape immunity in the lungs. Immunology 2020 (n/a(n/a).
[19] Huffnagle GB, Dickson RP, Lukacs NW. The respiratory tract microbiome and lung inflammation: a two-way street. Mucosal Immunol 2017;10(2):399–406.
[20] Dickson RP, Huffnagle GB. The lung microbiome: new principles for respiratory microbiology in health and disease. PLoS Pathog 2015;11(7):e1004923.
[21] Dickson RP, Erb-Downward JR, Freeman CM, Mescolcey L, Beck JM, Huffnagle GB, et al. Spatial variation in the healthy human lung microbiome and the adapted island model of lung biogeography. Ann Am Thorac Soc 2015;12(6):821–30.
[22] Dickson RP, Martinez FJ, Huffnagle GB. The role of the microbiome in exacerbations of chronic lung diseases. Lancet 2014;384(9944):691–702.
[23] Durack J, Lynch SV, Narvis S, Bhakta NR, Beigelman A, Castro M, et al. Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment. J Allergy Clin Immunol 2017;140(1):65–75.
[24] Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bosley C, et al. Disordered microbial communities in asthmatic airways. PLoS ONE 2010;5(1):e8578.
[25] Spacova I, Ceuppens JL, Seys SF, Petrova MI, Lebeer S. Probiotics against airway allergy: host factors to consider. Dis Model Mech 2018;11(7):dmx206.
[26] Pragman AA, Kim HB, Reilly CS, Wendt C, Isaacson RE. The lung microbiome in severe and moderate chronic obstructive pulmonary disease. PLoS ONE 2012;7(10):e47305.
[27] Sze MA, Dimitriu PA, Hayashi S, Elliott WM, McDonough JE, Gosselin JV, et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185(10):1073–80.
[28] Feigelman R, Kahler CR, Baty F, Ransouli F, Kleiner RL, Kohler P, et al. Sputum DNA sequencing in cystic fibrosis non-invasive access to the lung microbiome and to pathogen details. Microbiome 2017;5(1):20.
[29] Frayman KB, Armstrong DS, Carzino R, Ferkol TW, Larkin EK, et al. The lower airway microbiome in early cystic fibrosis lung disease: a longitudinal analysis. Thorax 2017;72(12):1104–12.
[30] Greathouse KL, White JR, Vargas AJ, Bliskovsky VV, Beck JA, van Mahunen N, et al. Interaction between the microbiome and TP53 in human lung cancer. Genome Biol 2018;19(1):123.
[31] Lee SH, Sung JY, Dong C, Kim SY, Song JH, et al. Characterization of microbiome in bronchoalveolar lavage fluid patients with lung cancer comparing with benign mass like lesions. Lung Cancer 2016;102(95):89–95.
[32] Wu BG, Segal LN. The lung microbiome and its role in pneumonia. Clin Chest Med 2018;39(4):677–89.
[33] Quinton LJ, Walkey AJ, Mizgerd JP. Integrative physiology of pneumonia. Physiol Rev 2018;98(3):1417–64.
[34] WHO. Pneumonia 2019 [Available from: https://www.who.int/news-room/fact-sheets/detail/pneumonia.
[35] WIKO. Pneumonia 2019 [Available from: https://www.who.int/news-room/q-a-detail/pneumonia.
[36] Gaddy NJ, Russell CD, McHugh MP, Mark H, Conway Morris A, Laurenson IF, et al. Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia. Clin Infect Dis 2016;62(7):817–23.
[37] Emonet S, Lazarveic V, Leemann Refondini C, Gaïa N, Leo S, Giraud M, et al. Identification of respiratory microbiota markers in ventilator-associated pneumonia. Intensive Care Med 2019;45(8):1082–92.
[38] Woo S, Park SY, Kim Y, Jeon JP, Lee JJ, Hong YJ. The dynamics of respiratory microbiota during mechanical ventilation in patients with pneumonia. J Clin Med 2020;9(3).
[39] Vázquez-Pérez JA, Carrillo CO, Iniguez-Garcia MA, Romero-Espinoza I, Marquez-Garcia JE, Falcon JL, et al. Abnormal microbiota profile in patients with human pulmonary tuberculosis and interstitial pneumonia. Microb Pathog 2020;139:103851.
[40] Wang H, Dai W, Qiu C, Li S, Wang W, Xu J, et al. Mycoplasma pneumoniae and Streptococcus pneumoniae pneumonias caused different microbial structure and correlation network in lung microbiota. J Thorac Dis; 2019.
[41] Rojas-Salazar C, Shiels MH, Tovchigrechko A, Schobel S, Chappell JD, Larkin EK, et al. Differences in the nasopharyngeal microbiome during acute respiratory tract infection with human rhinovirus and respiratory syncytial virus in infancy. J Infect Dis 2016;214(12):1924–8.
[42] Hamada S, Pirzadeh M, Carver KY, Deng JC. Respiratory Viral Infection-Induced Microbiome Alterations and Secondary Bacterial Pneumonia. Front Immunol 2018;9:2640-.
S. Khatiwada and A. Subedi

[44] Gu L, Deng H, Ren Z, Zhao Y, Yu S, Guo Y, et al. Dynamic Changes in the Microbiome and Mucosal Immune Microenvironment of the Lower Respiratory Tract by Influenza Virus Infection. Front Microbiol 2015;6:2491.

[45] Lloyd CM, Marshland BJ. Lung homeostasis: influence of age, microbes, and the immune system. Immunity 2017;46(4):59–61.

[46] Nanno M, Shiohara T, Yamamoto H, Kawakami K, Ishikawa H. gammadelta T cells: a descriptive study. Lancet 2020;395(10223):507–13.

[47] Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol 2020;92(4):424–32.

[48] Yang D, Xing Y, Song X, Qian Y. The impact of lung microbiota dysbiosis on immunity and asthma. N Engl J Med 2011;364(8):701–8.

[49] Coperchini F, Chiavoto I, Croce L, Magni F, Rotondi M. The Cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev 2020.

[50] Totura AL, Baric RS. SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. Curr Opin Immunol 2012;24(3):264–75.

[51] Strachan DP. Hay fever, hygiene, and household size. BMJ 1989;299(6710):1259–66.

[52] Ege MJ, Mayer M, Normand A-C, Genuneit J, Cookson WOCM, Braun-Andersen C, et al. Exposure to environmental microorganisms and childhood asthma. N Engl J Med 2011;364(8):701–9.